Cross-Sectional Study Shows Rising PPI Use in Chinese ACS and AF Patients at Discharge

This cross-sectional study analyzed prescription patterns among 531 Chinese patients diagnosed with acute coronary syndrome and atrial fibrillation. The research was conducted at the Cardiovascular Center of Beijing Tongren Hospital. The primary objective was to evaluate trends and influencing factors regarding proton pump inhibitor administration at discharge. No specific follow-up duration was reported for this observational analysis. Results spanned 2010 to 2018.

The study compared patients receiving proton pump inhibitor administration at discharge against a non-PPI group. Results indicated an increasing trend in PPI administration rates over time. Specifically, the rate rose from 21.3% during the 2010–2012 period to 63.5% during the 2016–2018 period. Overall, 47.8% of the cohort, representing 254 out of 531 patients, received a proton pump inhibitor. The p-value associated with the trend is listed as p in the source data. Prescribing behavior shifted significantly during the study period.

Safety data were not reported in this analysis. Adverse events, serious adverse events, discontinuations, and tolerability information were not reported. The study limitations were not explicitly detailed in the provided input. As a cross-sectional design, this evidence describes associations rather than causal relationships between PPI use and clinical outcomes. Practice relevance is limited by the lack of outcome data beyond prescription patterns. Clinicians should interpret these findings as descriptive trends within a specific hospital setting rather than generalizable guidelines. Generalizability is restricted to this single center.